Cargando…

Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials

Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic cancer treated with ramuciruma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Lingxue, Wang, Tong, Zhang, Qianqian, Yu, Sheng, Li, Wen, Yao, Senbang, Cheng, Huaidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705087/ https://www.ncbi.nlm.nih.gov/pubmed/36451771 http://dx.doi.org/10.1155/2022/2476469

Ejemplares similares

Identification of hub genes related to CD4(+) memory T cell infiltration with gene co-expression network predicts prognosis and immunotherapy effect in colon adenocarcinoma
por: Tang, Lingxue, et al.
Publicado: (2022)

A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma
por: Yu, Sheng, et al.
Publicado: (2023)

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
por: Tabernero, J, et al.
Publicado: (2018)

Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
por: Yen, Chia-Jui, et al.
Publicado: (2018)

The Managing Cancer and Living Meaningfully (CALM) Intervention Alleviates Chemotherapy-Related Cognitive Impairment in Patients with Breast Cancer by Modulating Pan-Immune-Inflammation Values
por: Yao, Senbang, et al.
Publicado: (2022)

Effects of Managing Cancer and Living Meaningfully on Cancer-Related Fatigue and Cytokine Levels in Gastrointestinal Cancer Patients
por: Cai, Yinlian, et al.
Publicado: (2023)

Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
por: Yao, Senbang, et al.
Publicado: (2022)

The alterations in event-related potential responses to pain empathy in breast cancer survivors treated with chemotherapy
por: Li, Wen, et al.
Publicado: (2022)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2022)

Effects of fear of cancer recurrence on subjective physical and mental health in breast cancer patients: The intermediary role of heart rate variability
por: Zhang, Qianqian, et al.
Publicado: (2023)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(†)
por: Obermannová, R., et al.
Publicado: (2016)

Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
por: Rezvani, Hamid, et al.
Publicado: (2022)

The role of the oxytocin system in the resilience of patients with breast cancer
por: Liu, Shaochun, et al.
Publicado: (2023)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
por: Cooper, Maryann R, et al.
Publicado: (2016)

The correlation between neutrophil-to-lymphocyte ratio, carcinoembryonic antigen, and carbohydrate antigen 153 levels with chemotherapy-related cognitive impairment in early-stage breast cancer patients
por: Yu, Sheng, et al.
Publicado: (2022)

Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label, Phase Ib Study
por: Lin, Chia‐Chi, et al.
Publicado: (2020)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017)

Re: Response to In regard to Ding et al. 2020: “Managing Cancer and Living Meaningfully (CALM) Intervention on Chemotherapy Related Cognitive Impairment in Breast Cancer Survivors”
por: Cheng, Huaidong, et al.
Publicado: (2023)

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
por: Arkenau, Hendrik‐Tobias, et al.
Publicado: (2018)

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
por: Masuishi, Toshiki, et al.
Publicado: (2023)

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Ramucirumab: A New Therapy for Advanced Gastric Cancer
por: Oholendt, Andrea Landgraf, et al.
Publicado: (2015)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)
por: Lorenzen, Sylvie, et al.
Publicado: (2023)

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer
por: Sakaguchi, Tadashi, et al.
Publicado: (2020)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
por: Nishio, Makoto, et al.
Publicado: (2022)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma
por: Nishioka, Naoya, et al.
Publicado: (2018)

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
por: Chau, Ian, et al.
Publicado: (2020)

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
por: Kasuya, Kayoko, et al.
Publicado: (2020)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Efficacy and safety of ramucirumab treatment in patients with advanced colorectal cancer: A protocol for systematic review and meta analysis
por: Ju, Man, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ckmt53t8dppka9eisfhqtpi13q